Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Work In Process (2017 - 2024)

China Pharma Holdings filings provide 8 years of Work In Process readings, the most recent being $334430.0 for Q3 2024.

  • On a quarterly basis, Work In Process fell 50.59% to $334430.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $334430.0, a 50.59% decrease, with the full-year FY2023 number at $413597.0, down 25.77% from a year prior.
  • Work In Process hit $334430.0 in Q3 2024 for China Pharma Holdings, up from $87308.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $676885.0 in Q3 2023 to a low of $87308.0 in Q2 2024.
  • Median Work In Process over the past 5 years was $423493.0 (2020), compared with a mean of $431457.2.
  • Biggest five-year swings in Work In Process: skyrocketed 110.99% in 2020 and later plummeted 76.07% in 2024.
  • China Pharma Holdings' Work In Process stood at $662999.0 in 2020, then decreased by 15.97% to $557146.0 in 2021, then changed by 0.0% to $557146.0 in 2022, then dropped by 25.77% to $413597.0 in 2023, then fell by 19.14% to $334430.0 in 2024.
  • The last three reported values for Work In Process were $334430.0 (Q3 2024), $87308.0 (Q2 2024), and $242726.0 (Q1 2024) per Business Quant data.